Mode
Text Size
Log in / Sign up
Phase 3 N=216 Randomized Prevention

Girls OnGuard: HPV Vaccination Uptake Among African American Adolescent Females

Vaccination

Enrolled (actual)
216
Serious AEs
0.0%
Results posted
Aug 2014
Primary outcome: Primary: GARDASIL Vaccination Uptake and Compliance With Second and Third Doses — 12; 12; 8; 3 participants — p=>.05

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Girls OnGuard (Behavioral)
Age
Pediatric, Adult · 13+ yrs
Sex
Female
Sponsor
Emory University
Primary completion
Nov 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
GARDASIL Vaccination Uptake and Compliance With Second and Third Doses
12; 12; 8; 3; 6; 2 >.05
PRIMARY
Total Doses Received of HPV Vaccine
26; 17 =.12
SECONDARY
STD Incidence
35; 32 =.52

Summary

African American adolescent females seeking treatment for STIs are an underserved population at increased risk for HPV infection. While GARDASIL is an effective preventive vaccine, vaccination rates are low. Given the risk for HPV infection among this subgroup and the negative health effects associated with HPV, enhancing uptake of GARDASIL is necessary. The goal of this project is to promote GARDASIL vaccination through the development of a new multi-component, culturally-appropriate, interactive DVD. We propose to recruit 280 unmarried African American adolescent females, 13-18 years of age, from participating clinic sites in Atlanta, Georgia. While seeking clinical services, adolescents will be contacted and invited to participate in the proposed study. Eligible adolescents will be required to provide written assent/consent prior to participation. Adolescents who are eligible and willing to participate in the project will complete a short survey on a laptop computer. The survey is designed to assess adolescents' risk taking and preventive behaviors. After they complete the survey, adolescents will be assigned at random to one of two groups. In one group, adolescents will watch a short (10 min), interactive DVD designed to promote HPV awareness and initial GARDASIL vaccination and receive a keepsake to help them remember to return to the clinic for their second and third vaccine doses. In the second group, adolescents will watch an equally short (10 min) DVD on healthy lifestyles and behaviors. All adolescents are eligible to receive the GARDASIL vaccine at participating study clinics as part of their routine standard of care. With the help of clinic staff, participant medical records will be reviewed over a 7 month period to assess vaccination rates. Vaccination rates from adolescents who received the interactive HPV/GARDASIL awareness DVD will be compared to the group of adolescents who received the healthy lifestyles DVD. It is hypothesized that study participants receiving the interactive DVD intervention that promotes HPV awareness will have higher vaccination rates over time.

Eligibility Criteria

Inclusion Criteria

  • African American
  • Female
  • Age 13-18 years
  • Seeking reproductive/STI services at participating clinic
  • Ability to give written informed consent or assent

Exclusion Criteria

  • Pregnant
  • Married
  • Already received the HPV vaccine
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00813319). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search